**Name of journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 16781**

**Columns: REVIEW**

**Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma**

Baran B. Prevention of HBV-related HCC

Bulent Baran

**Bulent Baran,** Department of Gastroenterology, Koç University Hospital, Zeytinburnu, 34010 Istanbul, Turkey

**Author contributions:** Baran B performed literature search and wrote the whole manuscript.

**Conflict-of-interest:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Bulent Baran, MD, FEBG,** Department of Gastroenterology, Koç University Hospital,Zeytinburnu, 34010 Istanbul, Turkey.drbulentbaran@gmail.com

**Telephone:** +90-850-2508250

**Fax:** +90-212-3112277

**Received:** January 29, 2015

**Peer-review started:** February 2, 2015

**First decision:** April 10, 2015

**Revised:** May 6, 2015

**Accepted:** June 18, 2015

**Article in press:**

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is among the most common cancer types and causes of cancer related mortality worldwide. Almost 50% of all hepatocellular carcinoma cases globally are attributable to chronic hepatitis B virus (HBV) infection. The incidence rates of hepatocellular carcinoma in untreated Asian subjects with hepatitis B virus infection was estimated to be 0.2% in inactive carriers, 0.6% for those with chronic hepatitis without cirrhosis, and 3.7% for those with compensated cirrhosis. In Western populations, HCC incidences are reported to be 0.02% in inactive carriers, 0.3% in subjects with chronic hepatitis without cirrhosis, and 2.2% in subjects with compensated cirrhosis. Despite effective antiviral treatment options which are able to transform chronic hepatitis into an inactive carrier state, the risk of hepatocellular carcinoma cannot be fully ruled out to exclude those patients from surveillance. Newer nucleos(t)ide analogues as entecavir and tenofovir are very potent in terms of sustained virological suppression which leads to improved liver histology. However, they do not have any influence on the cccDNA or integrated DNA of hepatitis B virus in the liver. Nonetheless, viral replication is the only modifiable component among the established risk factors for HBV-related HCC with the current treatment options. In this review, it was aimed to summarize cumulative evidence behind the concept of prevention of hepatitis B virus related hepatocellular carcinoma by nucleos(t)ide analogues, and to discuss remaining obstacles to eliminate the risk of hepatocellular carcinoma.

**Key words:** Hepatitis B virus; Hepatocellular carcinoma; Prevention; Nucleos(t)ide analogues; Risk factors

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** After the introduction of potent nucleos(t)ide analogues with high genetic barrier to resistance, maintaining long-term virological suppression is achievable in almost all patients with chronic hepatitis B. The currently recommended first-line antiviral drugs, entecavir and tenofovir, can significantly reduce hepatocellular carcinoma incidence, but the observed risk under efficient therapy is not zero in the long-term. There are established risk factors including age, gender, family history, low platelet levels, presence of cirrhosis or severity of liver disease, which should be incorporated into the clinical decision making to differentiate those patients under risk of developing hepatocellular carcinoma.

Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. *World J Hepatol* 2015; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the fifth most common cancer and third most common cause of cancer related mortality worldwide[[1](#_ENREF_1)]. HCC virtually always develops within a background chronic liver disease. Globally, almost 50% of all HCC cases are attributable to chronic hepatitis B virus (HBV) infection[[2](#_ENREF_2)]. HCC incidence is highly variable in different geographic locations and the distribution of the disease may be different even among ethnic groups living in the same country[[1](#_ENREF_1)]. These differences are most probably due to geographical variations in the prevalence of hepatitis viruses. In Sub-Saharan Africa and Asia most cases of HCC develop in the presence of chronic hepatitis B (CHB) infection (up to 60%), however in western countries only up to 20% of cases can be attributed to HBV infection[[2](#_ENREF_2)]. Fortunately, after the introduction of universal vaccination programs throughout the world, the incidence of CHB infection was significantly decreased[[3](#_ENREF_3)]. In the countries that have adopted the HBV vaccination program, a significant decrease in carrier rates as well as complications including HCC development have been experienced[[4](#_ENREF_4)]. However, HBV infection is still a major health problem in most parts of the world and development of HCC is an important complication of chronic infection, even in inactive carrier patients[[5](#_ENREF_5)]. In cirrhotic patients, surveillance for HCC increases the possibility of an earlier diagnosis that gives the patient a chance to undergo curative treatments[[2](#_ENREF_2)]. However, current recommendations for screening of HCC in patients at risk is far from being satisfactory, and prognosis remains poor because treatment options are rather non-curative in advanced stages of the disease[[6](#_ENREF_6)]. In this context, it is imperative to implement preventive strategies in patients with CHB infection. Despite effective antiviral treatment options which are able to transform chronic hepatitis into an inactive carrier state, the risk of HCC cannot be fully ruled out to exclude those patients from surveillance.

**LITERATURE STUDY**

In this review, it is sought to summarize the cumulative evidence on the role of antiviral therapy with NAs in the chemoprevention of HCC. Studies on prevention of HBV-related HCC were identified through electronic and manual search using online databases including MEDLINE and Web of Science. The relevant papers and conference proceedings in English language published from January, 2001 to January, 2015 were searched using following keywords: hepatocellular carcinoma, hepatitis B virus, prevention, recurrence, curative treatment, resection, nucleos(t)ide analogue, lamivudine, adefovir, telbivudine, entecavir, tenofovir. Selected studies were grouped according to one of the following topics: (1)NAs in chemoprevention of HCC; (2) HCC risk in patients who clear hepatitis B surface antigen (HBsAg); and (3) HCC recurrence risk in patients with HBV-related HCC after curative treatments. Both randomized-controlled and non-randomized studies were considered for inclusion. Uncontrolled studies were excluded unless an estimated HCC risk model was used to assess efficacy of NAs on HCC incidence. Reference lists of all papers, including reviews and meta-analyses, found during electronic search were checked manually to find relevant articles. The papers which were judged to be pertinent to the topic exceeded 100, and the number of included full-length articles were 51.

**HBV AND THE RISK OF HCC**

The association between HBV infection and development of HCC is well-established and has been demonstrated in several studies. In an early prospective controlled study from Asia, it was shown that the annual incidence of HCC was 0.5% in HBV-infected individuals; and the risk increased with age where annual incidence reached 1% at the age of 70[[7](#_ENREF_7)]. HBV-infected subjects were found to be 100 times more likely to develop HCC compared to uninfected subjects. The incidence ratio for HCC was even higher as much as 2.5% per year in patients with known cirrhosis. In a recent study by Chen et al[[5](#_ENREF_5)], a lesser but still substantial risk of HCC development was reported in an Asian cohort of patients with inactive HBV infection. In this study, the authors reported an annual incidence rate of 0.06% for HCC development with a relative risk of 4.4 compared to uninfected controls. In Western populations most studies are inadequate to drive conclusions and results are variable. This discrepancy between incidence rates among studies is probably due to the different patient settings (referral or population-based) and definitions for the HBV carrier state. Annual rates as high as 0.47% was reported in a study by Sherman *et al*[[8](#_ENREF_8)], which can be explained by high prevalence (71%) of Asian background in this North American population. Yet, most studies reported that annual incidence of HBV-related HCC in Europe or North America seems to be less significant[[9](#_ENREF_9),[10](#_ENREF_10)], and it is generally accepted to be around or less than 0.2%[[11](#_ENREF_11)]. Therefore, it is not clear if surveillance is worthwhile or when is it cost-effective to start screening in Caucasian populations. HBV-infected patients with African ancestry seem to possess a higher risk of developing HCC, particularly at a younger age[[12](#_ENREF_12)]. A database analysis from the United States reported higher incidence rates among Asians/Pacific Islanders, blacks, Native Americans/Alaska Natives, compared to people with European ancestry[[13](#_ENREF_13)]. Although HCC may arise in the setting of inactive HBV infection, most patients with HBV who develop HCC have cirrhosis either long-standing or undiagnosed at the time of HCC diagnosis[[14](#_ENREF_14),[15](#_ENREF_15)]. In a review of cohort studies[[16](#_ENREF_16)], it was summarized that incidence rates of HCC in Asian subjects with HBV infection was estimated to be 0.2% in inactive carriers, 0.6% for those with chronic hepatitis without cirrhosis, and 3.7% for those with compensated cirrhosis. With an attention to inadequacy of studies in Western populations, they calculated an annual incidence rate of 0.02% in inactive carriers, 0.3% in subjects with chronic hepatitis without cirrhosis, and 2.2% in subjects with compensated cirrhosis.

There are a number of factors other than cirrhosis and ethnicity that have been reported to increase HCC risk among HBV carriers. Patient related factors include male gender, older age, high alcohol consumption and family history of HCC, and viral factors include duration of infection, higher viral replication, HBV genotype, and co-infection [hepatitis C, hepatitis D or human immunodeficiency virus (HIV)][[14](#_ENREF_14)]. Recently, it was also shown that high levels of HBsAg titer (HBsAg ≥ 1000 IU/mL) is associated with increased risk of HCC in CHB patients with low viral load (HBVDNA < 2000 IU/mL)[[17](#_ENREF_17)].

**MECHANISMS OF HBV-ASSOCIATED HEPATOCARCINOGENESIS**

An interaction of complex mechanisms and pathways contribute to the initiation of hepatocarcinogenesis. HBV infection is among the most important risk factors for development of HCC, and can influence carcinogenesis by multiple ways. Chronic inflammation, a driving factor in many types of cancers, is an important pathogenetic mechanism for development of HBV-related HCC. Chronic inflammation in the liver is characterized by sustained hepatic damage, damage-induced apoptosis, hepatocyte death/regeneration cycle, and tissue repair. In addition to continuous cycle of cell death and regeneration, constant activation of inflammatory signaling and increased cytokine production by innate and adaptive immune system contribute to generation of reactive oxygen and nitrogen species which can cause damage to important cellular components including cytoplasmic membrane lipids, intracellular proteins and DNA[[18](#_ENREF_18),[19](#_ENREF_19)]. Genomic instability and alterations in epigenetic regulation of genes can cause inappropriate gene expression and enhanced proliferation of induced cells leading to neoplastic changes in susceptible individuals (Figure 1)[[20](#_ENREF_20)]. Interestingly, induced cells may have clonal properties which were demonstrated in experimental models that show clonal hepatocyte repopulation is a major risk factor for HCC development[[21](#_ENREF_21),[22](#_ENREF_22)]. In addition to non-specific hepatocarcinogenesis by chronic inflammation, HBV has unique virus-specific mechanisms involving the viral proteins HBx and preS/S, and the insertional mutagenesis with integration of HBV-DNA into the host genome that alters the expression of endogenous genes or induces chromosomal instability, and causes epigenetic changes including alterations in genomic methylation and regulation of microRNA expression (Figure 2)[[23](#_ENREF_23)].

**NAS IN CHEMOPREVENTION OF HCC**

The real key for certain prevention of HBV-related HCC is vaccination against the virus for newborns and people at risk. However in the absence of definitive curative treatment, there is a need for accurate risk estimation and modification in patients with chronic infection. Among the established risk factors for HBV-related HCC, patient or virus-related factors cannot be modified except viral replication. In a large prospective cohort by REVEAL-HBV study group, the relationship between HBV-DNA titer and HCC risk was demonstrated without any doubt[[24](#_ENREF_24),[25](#_ENREF_25)]. Currently, there are five NAs approved for the treatment of patient with CHB: lamivudine, telbivudine, adefovir, entecavir and tenofovir disoproxil[[26](#_ENREF_26)]. In the era of antiviral drugs with high barrier to resistance, we can suppress HBV-DNA in almost all patients receiving NAs, but the question remains if treatment prevents the development of HCC in every patient.

Lamivudine is a potent [reverse transcriptase inhibitor](http://en.wikipedia.org/wiki/Reverse-transcriptase_inhibitor) which was originally developed for the treatment of patients with HIV infection. It is the first oral antiviral drug that was approved for treatment of patients with CHB. Lamivudine monotherapy in patients with CHB is associated with ALT normalization, HBV-DNA suppression, hepatitis B “e” antigen (HBeAg) seroconversion[[27](#_ENREF_27),[28](#_ENREF_28)], and histological improvement (regression of necroinflammation and fibrosis) in the long-term[[29](#_ENREF_29)]. The role of NAs to prevent HCC has been thoroughly investigated in multiple studies but the largest number of studies available considered only lamivudine. The studies which investigated effects of NAs in reduction of HCC risk in CHB are summarized in Table 1. In a study by Liaw *et al*[[30](#_ENREF_30)], which evaluated long-term benefits of lamivudine monotherapy included 651 CHB patients with biopsy-proven advanced fibrosis or cirrhosis in a prospective randomized-placebo controlled setting. This pivotal study was terminated early due to significant beneficial effects seen in the treatment arm. Specifically, HCC development was observed in 3.9% of the patients in the treatment group and 7.4% of those in the placebo group with a hazard ratio of 0.49 (*P* = 0.047). In the same year, AISF (Italian Association for the Study of Liver Disease) Lamivudine Study Group investigated the effect of lamivudine treatment on the outcome of patients with HBeAg-negative chronic hepatitis B in a multicenter retrospective study[[31](#_ENREF_31)]. They found that cirrhotic patients with maintained virological response were less likely to develop HCC and disease worsening. But, presence of cirrhosis and virological breakthrough were independently related to mortality and development of HCC. In another randomized-controlled trial by Chan *et al*[[32](#_ENREF_32)], HBeAg-negative CHB patients were enrolled to lamivudine (100 mg/d) or placebo arms to investigate the efficacy of 2-year lamivudine treatment. Apparently, they did not find a risk reduction for HCC, but the study was not designed to answer this question and sample size was too small to get conclusions. Owing to undeniable beneficial effects of lamivudine therapy in CHB, subsequent randomized-controlled studies cannot be conducted to evaluate the influence of NAs. Thereafter, multiple case-control studies and prospective or retrospective cohort studies using historical controls were published. In a retrospective cohort study in Japan by Matsumoto *et al*[[33](#_ENREF_33)], which included 377 treated patients (lamivudine 100 mg/d) *vs* 377 matched untreated controls showed a significant risk reduction for HCC in treated cohort (0.4% per year *vs* 2.5% per year, *P* < 0.001). Several other Asian cohort studies from China[[34](#_ENREF_34),[35](#_ENREF_35)], Korea[[36-38](#_ENREF_36)] and India[[39](#_ENREF_39)] also confirmed the protective effect of antiviral therapy with lamivudine against development of HCC. The evidence behind HCC chemoprevention with oral antivirals comes largely from Asian cohort studies; however data obtained in Caucasian populations also exists. In a European cohort study from Greece, Papatheodoridis *et al*[[40](#_ENREF_40)] reported that lamivudine (with adefovir switch or add-on therapy when required) treatment significantly improved survival and reduced the risk of major events including HCC compared to interferon non-sustained responders and untreated controls.

Despite these encouraging results of lamivudine monotherapy, the development of resistant strains of HBV have been the main problem since it was introduced into the clinical practice. An important finding of the study by Liaw *et al*[[30](#_ENREF_30)] was that clinical deterioration defined as ≥ 2 increase in Child-Pugh score was significantly more frequent in patients who develop YMDD mutation under lamivudine treatment. In a large cohort study from Korea, lamivudine treatment reduced the incidence of HCC both in patients with CHB and cirrhosis, yet the risk reduction was significant only for compensated cirrhotic patients and when the viral suppression was sustained[[37](#_ENREF_37)]. Patients with virological breakthrough or suboptimal response during lamivudine therapy were shown to have an increased risk for HCC which was comparable to untreated controls. Kurokawa *et al*[[41](#_ENREF_41)] evaluated 283 patients with CHB treated with lamivudine 100 mg/d in an uncontrolled cohort study. They found that maintained virological response, presence of cirrhosis, and age are independent risk factors for development of HCC in patients under lamivudine therapy.

In the era of NAs with high genetic barrier against resistance, entecavir and tenofovir are the only oral antiviral drugs recommended by major society treatment guidelines for CHB[[26](#_ENREF_26),[42](#_ENREF_42),[43](#_ENREF_43)]. However, the evidence behind these novel oral antivirals regarding HCC risk reduction is scarce. In the largest retrospective nationwide CHB cohort from Taiwan[[44](#_ENREF_44)], the investigators included 21595 matched patients in the treatment and control groups. Most of the patients were treated by lamivudine, yet 5748 patients received entecavir 0.5 mg/day. The treated cohort had a significantly lower 7-year incidence of HCC (7.32%; 95%CI: 6.77%-7.87%) than controls (22.7%; 95%CI: 22.1%-23.3%; *P* < 0.001). After adjusting for confounding factors, NA treatment was associated with a reduced risk of HCC, with an adjusted hazard ratio of 0.37 (95%CI: 0.34–0.39; *P* < 0.001). However, the authors did not report if there were any differences between lamivudine and entecavir treated patients regarding HCC incidence. In a randomized trial of 191 patients with decompensated cirrhosis, entecavir-treated patients tended to have a lower incidence of HCC than those treated with adefovir, but the risk reduction was not statistically significant (HR = 0.74, 95%CI: 0.46-1.18, *P* = 0.20)[[45](#_ENREF_45)]. A recent study from Japan that compared the incidence of HCC in entecavir-treated patients and a matched historical cohort of untreated patients (316 *vs* 316 patients), the investigators found a significantly reduced risk of HCC in the treated group (5 year incidence rates were 3.7% and 13.7 for the treatment and control groups, respectively; *P* < 0.001)[[46](#_ENREF_46)]. They also compared treatment effect between matched entecavir and lamivudine-treated patients without rescue therapy. It was reported that when the control group was taken as reference HCC risk reduction was more profound in entecavir-treated cirrhotic patients than it is for lamivudine-treated cirrhotic patients (*P* < 0.001 *vs* *P* = 0.019). Of note, this effect was seen in cirrhotic patients but not in non-cirrhotics. In a study from China by Wong *et al*[[47](#_ENREF_47)], the cumulative probability of HCC between entecavir and untreated historical controls were comparable (*P* = 0.82). However, entecavir-treated patients with radiological cirrhosis had a significantly lower 5-year cumulative probability of HCC (13.8% *vs* 26.4%, *P* = 0.036) compared to the untreated patients with cirrhosis. This effect was more profound in cirrhotic patients with maintained virological suppression. On the other hand, entecavir-treated patients with cirrhosis who failed to achieve undetectable HBVDNA had a comparable risk of HCC with the untreated patients. In a recent multicenter study from Taiwan[[48](#_ENREF_48)], 1123 patients with HBV-related cirrhosis treated with entecavir were compared to 503 historical controls with HBV-related cirrhosis. All patients had baseline serum HBV-DNA level >2000 IU/mL. Although treated patients were significantly older and had more advanced liver disease compared to historical controls, entecavir treatment was shown to be associated with an adjusted hazard ratio of 0.40 (95%CI: 0.27-0.60) in cirrhotic patients. After adjusting for age, the multivariate analysis showed that male gender, no treatment, lower albumin level and lower platelet count were independent risk factors associated with HCC development.

There are very few data regarding treatment effect of tenofovir on HCC incidence. One of them comes from post-hoc analysis of the registration trial of tenofovir, which was reported as an abstract. In this report by Sievert *et al*[[49](#_ENREF_49)], investigators included 641 patients with CHB receiving open-label tenofovir therapy for 6 years and compared HCC incidence with the estimated risk calculated by REACH-B model[[50](#_ENREF_50)]. They reported that 14 tenofovir-treated patients (6 of them were cirrhotic) developed HCC during the follow-up and the incidence of HCC decreased with a standardized incidence ratio of 0.45 (95%CI: 0.23-0.91) compared to the estimated risk. Despite the low number of HCC cases in this study, they concluded by emphasizing continued surveillance for CHB patients receiving long term oral antiviral treatment.

There are several meta-analyses or systematic reviews that confirmed the beneficial effects of NAs in the prevention of HCC in CHB. In a systematic review by Papatheodoridis *et al*[[51](#_ENREF_51)], 21 studies were reviewed and 3 of them which were of high quality and included untreated controls. In the pooled analysis of 3 studies, HCC was detected significantly less frequently in treated than in untreated patients (2.8% *vs* 6.4%, respectively, *P* = 0.003). Interestingly, they found that incidence of HCC was significantly higher in untreated patients even when compared to treated patients with virological breakthroughs or no response. Similarly, other meta-analyses confirmed these results regarding the influence of NAs on HCC risk (Table 2)[[52-54](#_ENREF_52)].

Although it is evident to say that antiviral therapy decrease HBV-related HCC incidence when compared with the natural course of the disease, there are sufficient data showing that antiviral therapy does not eliminate the HCC risk completely, even in non-cirrhotic patients with sustained virological suppression. Papatheodoridis *et al*[[55](#_ENREF_55)] included 818 patients with HBeAg-negative CHB treated with NAs in a retrospective study investigating HCC incidence. All patients were treated with NAs starting with lamivudine monotherapy, and during a median follow-up of 4.7 years 49 patients (6%) eventually developed HCC. The study demonstrated a trend for lower cumulative HCC incidence in CHB patients with virological on-therapy remission (*P* = 0.076), which was defined as maintained undetectable HBV-DNA (< 200 IU/mL). However, virological remission did not significantly influence the incidence of HCC in patients with cirrhosis (0.327). Moreover, multivariate analysis revealed that age, gender and cirrhosis were independently associated with HCC risk regardless of virological remission. In a recent study by Arends *et al*[[56](#_ENREF_56)], 14 of 744 patients (42% Caucasian ethnicity) with CHB developed HCC during a median follow-up of 167 wk. Nine (64%) patients among them had cirrhosis at baseline, and 12 patients developed HCC even after achieving virological response (HBV-DNA < 80 IU/mL). The 5-year cumulative incidence rate of HCC was reported to be low for non-cirrhotic patients, yet it was significantly higher for cirrhotic patients (2.1% *vs* 10.9%, respectively*, P* < 0.001).

Several studies investigated independent risk factors associated with HCC development in patients receiving NAs. The factors commonly attributed to HCC risk in patients receiving NAs were age, male gender, duration of disease, presence of cirrhosis and no virological response[[41](#_ENREF_41),[51](#_ENREF_51),[55](#_ENREF_55),[57-59](#_ENREF_57)]. Recently in a large European retrospective multicenter cohort of 1666 patients with CHB (all Caucasian) treated with entecavir or tenofovir, 71 patients (4.3%) developed HCC within a median follow-up duration of 39 months (range, 8-140 months)[[60](#_ENREF_60)]. The importance of this study is that there was little information available regarding the risk factors of HCC in Caucasian patients treated with novel antiviral drugs. The authors reported an annual incidence rate of 1.37 (95%CI: 1.09-1.73) per 100 patient. The cumulative probability of developing HCC reached 8.7% after 5 years of antiviral therapy. In multivariate Cox regression analysis they found age, male gender, low platelet levels (< 100000/mm3), and liver disease severity were independently associated with subsequent development of HCC. Of note, they did not find a significant association between virological remission under treatment and risk of HCC development, which was contrary to previous studies. However, this result is probably related to the high virological remission rate (92%) under antiviral treatment. A recent study from Turkey; which investigated the risk of HCC development in 641 CHB patients on-therapy; showed that cirrhosis, NAs with low-genetic barrier against resistance, and development of resistance or virological breakthrough were independent predictors of HCC development[[61](#_ENREF_61)].

**HCC RISK IN PATIENTS WHO CLEAR HBSAG**

Whether it is spontaneous or therapy-induced, HBsAg clearance with or without anti-HBs seroconversion is considered highly beneficial. Although HBsAg loss or seroconversion has been the ultimate goal in the treatment of CHB, it is rarely achievable with the available NA options which have no influence on intrahepatic cccDNA of HBV. Nonetheless, it is still the holy grail of a treatment course which can be achieved by only a small group of patients, even in the long-term. However, until recently data was insufficient to determine if it is reasonable to exclude those patients who achieve HBsAg loss or seroconversion from routine clinical follow-up. Although there is evidence showing that disease progression may still occur after HBsAg loss[[62](#_ENREF_62)], the common practice have been continuing follow-up and HCC screening only in those with cirrhosis. This seems to be an evidence-based approach, because cirrhosis is the major risk factor for HCC and should be considered a premalignant condition even after HBsAg loss or seroconversion[[63](#_ENREF_63)]. In a recent study by Simonetti *et al*[[64](#_ENREF_64)], 1271 Alaskan native patients with CHB were included in a prospective population-based cohort study, and 158 patients achieved HBsAg loss during a mean follow-up duration of 19.6 years. The authors reported that 6 patients (2 of them were cirrhotic) developed HCC during a mean follow-up of 7.3 years after HBsAg clearance. Although the HCC incidence after HBsAg clearance was reported to be significantly lower than the rate in those who remained seropositive, the risk was still high enough to justify continuum of periodic follow-up visits with HCC surveillance.

**HCC RECURRENCE RISK IN PATIENTS WITH HBV-RELATED HCC AFTER CURATIVE TREATMENTS**

Despite advances in surgical techniques, survival after curative resection for HBV-related HCC remains dissatisfactory with recurrence rates of more than 50%[[65](#_ENREF_65)]. There is no proven adjuvant chemotherapeutic regimen that can reduce recurrence risk or improve patient survival after curative resection. However, the above mentioned body of data provides solid evidence that antiviral therapy in patients with CHB or cirrhosis reduces the risk of HCC development, leading to the notion that antiviral therapy might prevent recurrence and improve survival after curative therapy. There is convincing evidence that persistent high viremia is associated with increased risk of HCC recurrence in CHB patients who underwent resection for HBV-related HCC[[66](#_ENREF_66),[67](#_ENREF_67)]. Therefore, the aim has been focused on suppression of persistent HBV replication, which occurs in almost all patients after liver resection and can severely reduce liver function and survival[[68](#_ENREF_68)]. Initial studies with small sample sizes did not find any significant effect of NAs to prevent HCC recurrence[[69-71](#_ENREF_69)]. In the first study that demonstrated a beneficial effect, Kubo *et al*[[72](#_ENREF_72)] found a lower 5-year disease-free survival rate after surgery in the lamivudine-treated group than control group. Subsequent studies provided conflicting results most probably due to the insufficient number of patients included, treatment heterogeneity (resection, local ablation, chemoembolization), and short duration of follow-up after resection (Table 3). For example, Chan et al[[73](#_ENREF_73)] reported a significantly higher 5-year tumor-free survival rates in the treatment group (42 patients, lamivudine 100 mg/day or entecavir 0.5 mg/d) than in the control group (94 patients) (51.4% *vs* 33.8%, respectively, *P* = 0.05). In contrast, Li *et al*[[74](#_ENREF_74)] demonstrated a higher but insignificant 1-year tumor free survival after curative hepatectomy in treated (Lamivudine ± adefovir) *vs* control groups (23.3% *vs* 8.3%, respectively, *P* = 0.072). Yet, the duration of follow-up after resection was too short to get conclusions. A larger study with a longer duration of follow-up in a retrospective nationwide cohort by Wu *et al*[[75](#_ENREF_75)] demonstrated a significantly reduced HCC recurrence rate in patients receiving NAs after liver resection. Two recently published randomized-controlled trials and several meta-analyses (Table 4) also confirmed these results which were obtained from retrospective cohort studies[[65](#_ENREF_65),[76-79](#_ENREF_76)].

**CONCLUSION**

In terms of HBV and hepatocarcinogenesis, it is important to emphasize that unlike other chronic liver diseases, HCC is not always seen on a background of advanced fibrosis or cirrhosis in CHB patients. Many studies confirmed the concept of suppression of HBV replication for chemoprevention of HCC in either primary or secondary prevention settings. Many of those studies are not perfect, but cumulative evidence shows an undeniable beneficial effect of NAs. Although the effect of modern NAs cannot be assessed in prospective-controlled trials which include placebo-treated or untreated patients in the control groups, there is no doubt that entecavir or tenofovir can provide greater and long-term virological suppression leading to reduced HCC incidence and better patient survival. Regardless of the antiviral treatment, several risk factors including but not limited to old age, male gender, longer duration of the disease, inadequate virological suppression and presence of cirrhosis are clearly associated with the ongoing risk of HCC development. Fortunately, inadequate virological suppression is not an issue with the newer antivirals, if patients are adherent with their medications. Recent evidence also shows that treatment with NAs cannot completely wipe out the risk of HCC, even in patients without risk factors or patients who clear HBsAg. Therefore, future studies should focus on differentiating patients who remain under risk despite effective antiviral therapy and providing cost-effective surveillance strategies in those patients under risk of HCC.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **European Association For The Study Of The Liver;** European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

3 **Ott JJ**, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012; **30**: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116]

4 **Chang MH**, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. *J Natl Cancer Inst* 2009; **101**: 1348-1355 [PMID: 19759364 DOI: 10.1093/jnci/djp288]

5 **Chen JD**, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. *Gastroenterology* 2010; **138**: 1747-1754 [PMID: 20114048 DOI: 10.1053/j.gastro.2010.01.042]

6 **El-Serag HB**. Hepatocellular carcinoma. *N Engl J Med* 2011; **365**: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]

7 **Beasley RP**, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. *Lancet* 1981; **2**: 1129-1133 [PMID: 6118576 DOI: 10.1016/S0140-6736(81)90585-7]

8 **Sherman M**, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. *Hepatology* 1995; **22**: 432-438 [PMID: 7543434 DOI: 10.1016/0270-9139(95)90562-6]

9 **Crook PD**, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. *Int J Epidemiol* 2003; **32**: 118-124 [PMID: 12690022 DOI: 10.1093/ije/dyg039]

10 **Villeneuve JP**, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, Côté J, Richer G. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. *Gastroenterology* 1994; **106**: 1000-1005 [PMID: 8143967]

11 **Kew MC**. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. *Pathol Biol* (Paris) 2010; **58**: 273-277 [PMID: 20378277 DOI: 10.1016/j.patbio.2010.01.005]

12 **Kew MC**, Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. *Gastroenterology* 1988; **94**: 439-442 [PMID: 2446950]

13 **Centers for Disease Control and Prevention (CDC).** Hepatocellular carcinoma - United States, 2001-2006. *MMWR Morb Mortal Wkly Rep* 2010; **59**: 517-520 [PMID: 20448528]

14 **El-Serag HB**. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012; **142**: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]

15 **Yang JD**, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011; **9**: 64-70 [PMID: 20831903 DOI: 10.1016/j.cgh.2010.08.019]

16 **Fattovich G**, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol* 2008; **48**: 335-352 [PMID: 18096267 DOI: 10.1016/j.jhep.2007.11.011]

17 **Tseng TC**, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. *Gastroenterology* 2012; **142**: 1140-1149.e3; quiz e13-e14 [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007]

18 **Lu H**, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res* 2006; **4**: 221-233 [PMID: 16603636 DOI: 10.1158/1541-7786.MCR-05-0261]

19 **Kundu JK**, Surh YJ. Inflammation: gearing the journey to cancer. *Mutat Res* 2008; **659**: 15-30 [PMID: 18485806 DOI: 10.1016/j.mrrev.2008.03.002]

20 **Wu Y**, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. *Cancer Lett* 2014; **345**: 164-173 [PMID: 23988267 DOI: 10.1016/j.canlet.2013.08.014]

21 **Mason WS**, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. *Proc Natl Acad Sci U S A* 2005; **102**: 1139-1144 [PMID: 15657132 DOI: 10.1073/pnas.0409332102]

22 **Marongiu F**, Doratiotto S, Montisci S, Pani P, Laconi E. Liver repopulation and carcinogenesis: two sides of the same coin? *Am J Pathol* 2008; **172**: 857-864 [PMID: 18321999 DOI: 10.2353/ajpath.2008.070910]

23 **Tarocchi M**, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. *World J Gastroenterol* 2014; **20**: 11630-11640 [PMID: 25206269 DOI: 10.3748/wjg.v20.i33.11630]

24 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]

25 **Chen CF**, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. *Gastroenterology* 2011; **141**: 1240-1248, 1248.e1-2 [PMID: 21703214 DOI: 10.1053/j.gastro.2011.06.036]

26 **European Association For The Study Of The Liver.** EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

27 **Dienstag JL**, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999; **341**: 1256-1263 [PMID: 10528035 DOI: 10.1056/NEJM199910213411702]

28 **Lai CL**, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; **339**: 61-68 [PMID: 9654535 DOI: 10.1056/NEJM199807093390201]

29 **Dienstag JL**, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003; **124**: 105-117 [PMID: 12512035 DOI: 10.1053/gast.2003.50013]

30 **Liaw YF**, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]

31 **Di Marco V**, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxì A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. *Hepatology* 2004; **40**: 883-891 [PMID: 15382125 DOI: 10.1002/hep.20381]

32 **Chan HL**, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. *Antivir Ther* 2007; **12**: 345-353 [PMID: 17591024]

33 **Matsumoto A**, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. *Hepatol Res* 2005; **32**: 173-184 [PMID: 16024289 DOI: 10.1016/j.hepres.2005.02.006]

34 **Yuen MF**, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. *Antivir Ther* 2007; **12**: 1295-1303 [PMID: 18240869]

35 **Ma H**, Wei L, Guo F, Zhu S, Sun Y, Wang H. Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis. *J Gastroenterol Hepatol* 2008; **23**: 1250-1258 [PMID: 18624896 DOI: 10.1111/j.1440-1746.2008.05499.x]

36 **Lee HJ**, Eun R, Jang BI, Kim TN. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. *Gut Liver* 2007; **1**: 151-158 [PMID: 20485632 DOI: 10.5009/gnl.2007.1.2.151]

37 **Eun JR**, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. *J Hepatol* 2010; **53**: 118-125 [PMID: 20471129 DOI: 10.1016/j.jhep.2010.02.026]

38 **Kim CH**, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. *J Gastroenterol Hepatol* 2012; **27**: 1589-1595 [PMID: 22554121 DOI: 10.1111/j.1440-1746.2012.07167.x]

39 **Das K**, Das K, Datta S, Pal S, Hembram JR, Dhali GK, Santra A, Chowdhury A. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. *Liver Int* 2010; **30**: 1033-1042 [PMID: 20492502 DOI: 10.1111/j.1478-3231.2010.02255.x]

40 **Papatheodoridis GV**, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. *Hepatology* 2005; **42**: 121-129 [PMID: 15962291 DOI: 10.1002/hep.20760]

41 **Kurokawa M**, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. *J Gastroenterol* 2012; **47**: 577-585 [PMID: 22231575 DOI: 10.1007/s00535-011-0522-7]

42 **Liaw YF,** Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatology International* 2012; **6**: 531-561 [PMID: 000304611200001 DOI 10.1007/s12072-012-9365-4]

43 **Lok AS,** McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

44 **Wu CY**, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. *Gastroenterology* 2014; **147**: 143-151.e5 [PMID: 24704525 DOI: 10.1053/j.gastro.2014.03.048]

45 **Liaw YF**, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. *Hepatology* 2011; **54**: 91-100 [PMID: 21503940 DOI: 10.1002/hep.24361]

46 **Hosaka T**, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013; **58**: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]

47 **Wong GL**, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology* 2013; **58**: 1537-1547 [PMID: 23389810 DOI: 10.1002/hep.26301]

48 **Su TH,** Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Peng CY, Chien RN, Mo LR, Huang YW, Chen MY, Lin CL, Chen TM, Wang HY, Tseng KC, Yang SS, Hsu SJ, Suk FM, Hu CT, Hsieh TY, Ming-jong B, Liang CC, Tseng TC, Chen CL, Kao JH. Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - A follow-up report of C-TEAM study. *Hepatology* 2014; **60**: 1284a-1285a

49 **Sievert W,** Strasser S, Gane E, George J, Weilert F, Flaherty JF, Dinh P, Schall RA, Martins EB, Yee L, Marcellin P, Kim WR. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. *J Gastroen Hepatol* 2013; **28**: 53-54

50 **Yang HI**, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011; **12**: 568-574 [PMID: 21497551 DOI: 10.1016/S1470-2045(11)70077-8]

51 **Papatheodoridis GV**, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. *J Hepatol* 2010; **53**: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]

52 **Zhang QQ**, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. *Virol J* 2011; **8**: 72 [PMID: 21324130 DOI: 10.1186/1743-422X-8-72]

53 **Singal AK**, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. *Aliment Pharmacol Ther* 2013; **38**: 98-106 [PMID: 23713520 DOI: 10.1111/apt.12344]

54 **Sung JJ,** Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2008; **28**: 1067-1077 [PMID: 18657133 DOI: 10.1111/j.1365-2036.2008.03816.x]

55 **Papatheodoridis GV**, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. *Gut* 2011; **60**: 1109-1116 [PMID: 21270118 DOI: 10.1136/gut.2010.221846]

56 **Arends P,** Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bommel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; for the VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. *Gut* 2014 Jul 10; pii: gutjnl-2014-307023 [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023]

57 **Yang SC**, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. *J Antimicrob Chemother* 2013; **68**: 2154-2163 [PMID: 23620466 DOI: 10.1093/jac/dkt147]

58 **Zoutendijk R**, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. *Gut* 2013; **62**: 760-765 [PMID: 22490523 DOI: 10.1136/gutjnl-2012-302024]

59 **Kim SS**, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. *Am J Gastroenterol* 2014; **109**: 1223-1233 [PMID: 24890440 DOI: 10.1038/ajg.2014.145]

60 **Papatheodoridis GV**, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015; **62**: 363-370 [PMID: 25195548 DOI: 10.1016/j.jhep.2014.08.045]

61 **Gokturk S,** Basar R, Ucar AR, Basgoze BH, Altinkaynak M, Buyukballi P, Alpaslan B, Baran B, Ormeci AC, Soyer OM, Evirgen S, Bakir B, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Virological Supression Does not Prevent the Development of Hepatocellular Carsinoma in Cirrhotic Patients with Genotype D Hepatitis B Infection. *Hepatology* 2013; **58**: 684A-685A

62 **Yuen MF**, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. *Gastroenterology* 2008; **135**: 1192-1199 [PMID: 18722377 DOI: 10.1053/j.gastro.2008.07.008]

63 **Villa E**, Fattovich G. No inflammation? No cancer! Clear HBV early and live happily. *J Hepatol* 2010; **52**: 768-770 [PMID: 20356646 DOI: 10.1016/j.jhep.2010.01.018]

64 **Simonetti J**, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. *Hepatology* 2010; **51**: 1531-1537 [PMID: 20087968 DOI: 10.1002/hep.23464]

65 **Wong JS**, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. *Aliment Pharmacol Ther* 2011; **33**: 1104-1112 [PMID: 21488914 DOI: 10.1111/j.1365-2036.2011.04634.x]

66 **Kim BK**, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. *Liver Int* 2008; **28**: 393-401 [PMID: 18028321 DOI: 10.1111/j.1478-3231.2007.01625.x]

67 **Cheung YS**, Chan HL, Wong J, Lee KF, Poon TC, Wong N, Lai PB. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. *Asian J Surg* 2008; **31**: 41-49 [PMID: 18490213 DOI: 10.1016/S1015-9584(08)60056-1]

68 **Huang G**, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. *Ann Surg* 2013; **257**: 490-505 [PMID: 22868358 DOI: 10.1097/SLA.0b013e318262b218]

69 **Piao CY**, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. *Acta Med Okayama* 2005; **59**: 217-224 [PMID: 16286955]

70 **Shuqun C**, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, Zhengfeng Y, Yuxiang Z, Peijun W. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. *Hepatogastroenterology* 2006; **53**: 249-252 [PMID: 16608033]

71 **Kuzuya T**, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. *J Gastroenterol Hepatol* 2007; **22**: 1929-1935 [PMID: 17914972 DOI: 10.1111/j.1440-1746.2006.04707.x]

72 **Kubo S,** Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, Habu D, Nishiguchi S. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. *Hepatol Res* 2007; **37**: 94-100 [PMID: 17300703 DOI: 10.1111/j.1872-034X.2007.00013.x]

73 **Chan AC**, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. *Arch Surg* 2011; **146**: 675-681 [PMID: 21690443 DOI: 10.1001/archsurg.2011.125]

74 **Li N**, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. *Ann Surg Oncol* 2010; **17**: 179-185 [PMID: 19727956 DOI: 10.1245/s10434-009-0694-z]

75 **Wu CY**, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. *JAMA* 2012; **308**: 1906-1914 [PMID: 23162861]

76 **Yin J**, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. *J Clin Oncol* 2013; **31**: 3647-3655 [PMID: 24002499 DOI: 10.1200/JCO.2012.48.5896]

77 **Huang G**, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. *Ann Surg* 2015; **261**: 56-66 [PMID: 25072444 DOI: 10.1097/SLA.0000000000000858]

78 **Sun P**, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. *PLoS One* 2014; **9**: e102761 [PMID: 25058587 DOI: 10.1371/journal.pone.0102761]

79 **Zhou Y**, Zhang Z, Zhao Y, Wu L, Li B. Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis. *World J Surg* 2014; **38**: 2395-2402 [PMID: 24791945 DOI: 10.1007/s00268-014-2586-z]

80 **Manolakopoulos S**, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. *Am J Gastroenterol* 2004; **99**: 57-63 [PMID: 14687142]

81 **Kumada T**, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. *J Hepatol* 2013; **58**: 427-433 [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025]

82 **Gordon SC**, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. *Clin Gastroenterol Hepatol* 2014; **12**: 885-893 [PMID: 24107395 DOI: 10.1016/j.cgh.2013.09.062]

83 **Coffin CS**, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. *Aliment Pharmacol Ther* 2014; **40**: 1262-1269 [PMID: 25312649 DOI: 10.1111/apt.12990]

84 **Yoshida H**, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, Tateishi R, Goto T, Shiina S, Kawabe T, Omata M. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. *Hepatol Int* 2008; **2**: 89-94 [PMID: 19669283 DOI: 10.1007/s12072-007-9020-7]

85 **Hung IF**, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. *Am J Gastroenterol* 2008; **103**: 1663-1673 [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x]

86 **Koda M**, Nagahara T, Matono T, Sugihara T, Mandai M, Ueki M, Ohyama K, Hosho K, Okano J, Kishimoto Y, Kono M, Maruyama S, Murawaki Y. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. *Intern Med* 2009; **48**: 11-17 [PMID: 19122351 DOI: 10.2169/internalmedicine.48.1534]

87 **Chuma M**, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. *J Gastroenterol* 2009; **44**: 991-999 [PMID: 19554391 DOI: 10.1007/s00535-009-0093-z]

88 **Urata Y**, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, Sakae M, Kaneda K, Ohata K, Nozawa A, Suehiro S. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci* 2012; **19**: 685-696 [PMID: 22203455 DOI: 10.1007/s00534-011-0489-z]

89 **Yang T,** Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. *Eur J Surg Oncol* 2012; **38**: 683-691 [PMID: 22621971 DOI: 10.1016/j.ejso.2012.04.010]

90 **Huang G**, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, Zhou WP, Wu MC. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. *Ann Surg Oncol* 2013; **20**: 1482-1490 [PMID: 23247982 DOI: 10.1245/s10434-012-2803-7]

91 **Ke Y**, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. *Cancer Biol Med* 2013; **10**: 158-164 [PMID: 24379991 DOI: 10.7497/j.issn.2095-3941.2013.03.006]

92 **Su CW,** Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. *PLoS One* 2013; **8**: e66457 [PMID: 23805222 DOI: 10.1371/journal.pone.0066457]

93 **Yeh YC**, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. *PLoS One* 2014; **9**: e102051 [PMID: 25025231 DOI: 10.1371/journal.pone.0102051]

94 **Zhang ZY**, Zhou ZQ, Zhou GW. Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm. *Eur J Gastroenterol Hepatol* 2014; **26**: 1116-1124 [PMID: 25003747 DOI: 10.1097/MEG.0000000000000153]

95 **Hann HW**, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann RS, Park KB, Dunn S, DiMarino AJ. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. *Cancer Med* 2014; **3**: 390-396 [PMID: 24519810 DOI: 10.1002/cam4.197]

96 **Nishikawa H**, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. *Hepatol Res* 2014; **44**: 608-620 [PMID: 23701455 DOI: 10.1111/hepr.12169]

97 **Chong CC**, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee KF, Lai PB, Chan HL. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. *Aliment Pharmacol Ther* 2015; **41**: 199-208 [PMID: 25413146 DOI: 10.1111/apt.13034]

98 **Miao RY**, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. *World J Gastroenterol* 2010; **16**: 2931-2942 [PMID: 20556841 DOI: 10.3748/wjg.v16.i23.2931]

**P-Reviewer:** Galvao FHF, Grassi A, Solinas A **S-Editor:** Tian YL

**L-Editor: E-Editor:**

|  |
| --- |
| **Table 1** **Summary of controlled studies investigating the effect of NAs on HCC risk among treated and untreated patients with chronic hepatitis B** |
| **Ref.** | **Country/region** | **Study type** | **Treatment** | **Number of pts (T/C)** | **Patient cohort** | **Follow-up (T/C),****Mean or median (yr)** | **Treatment outcome** |
| Liaw *et al*[[30](#_ENREF_30)] | Asia | RCT | Lamivudine (100 mg/d) | 436/215 | Advanced fibrosis or cirrhosis | 2.7/2.7 | Reduced HCC risk |
| Manolakopoulos *et al*[[80](#_ENREF_80)] | Greece | Case-control | Lamivudine(100 mg/d) | 30/30 | Decompensated cirrhosis | 1.5/1.8 | No risk reduction |
| Matsumoto *et al*[[33](#_ENREF_33)] | Japan | Retrospective cohort | Lamivudine(100 mg/d) | 377/377 | Chronic hepatitis B(any stage) | 2.7/5.3 | Reduced HCC risk |
| Papatheodoridis *et al*[[40](#_ENREF_40)] | Greece | Retrospective cohort | Lamivudine (adefovir switch or add-on when required) | 201/195 | HBeAg-negative chronic hepatitis B | 3.8/6.1 | Better overall survivalReduced risk of major events including HCC |
| Chan *et al*[[32](#_ENREF_32)] | China | RCT | Lamivudine(100 mg/d) | 89/47 | HBeAg-negative chronic hepatitis B | 2.5/2.5 | No risk reduction |
| Yuen *et al*[[34](#_ENREF_34)] | China | Prospective cohort | Lamivudine(25-100mg/d) | 142/124 | HBeAg-positive chronic hepatitis B | 7.5/9.0 | Reduced cirrhosis/HCC risk |
| Lee *et al*[[36](#_ENREF_36)] | Korea | Retrospective cohort | Lamivudine(100 mg/d) | 589/589 | Chronic hepatitis B (any stage) | 2.9/5.3 | Reduced HCC risk |
| Ma *et al*[[35](#_ENREF_35)] | China | Prospective cohort | Lamivudine(100 mg/d) | 41/176 | Cirrhosis | 3.16/NS | Reduced HCC risk  |
| Das *et al*[[39](#_ENREF_39)] | India | Case-control | Lamivudine or adefovir | 151/102 | Decompensated cirrhosis | 4.0/3.8 | Less HCC rate in treated group |
| Eun *et al*[[37](#_ENREF_37)] | Korea | Retrospective cohort | Lamivudine(100 mg/d) | 872/699 | Chronic hepatitis B(any stage) | 4.7/5.7 | Reduced HCC risk in cirrhotic pts with SVS |
| Kim *et al*[[38](#_ENREF_38)] | Korea | Retrospective cohort | Lamivudine and/or adefovir, or entecavir | 240/481 | Cirrhosis | 3.9/4.3 | Better overall survivalReduced HCC risk (borderline significance) |
| Hosaka *et al*[[46](#_ENREF_46)] | Japan | Retrospective cohort | Entecavir (0.5 mg/d) | 316/316 | Chronic hepatitis B(any stage) | 3.3/7.6 | Reduced HCC risk |
| Wong *et al*[[47](#_ENREF_47)] | China | Retrospective cohort | Entecavir (0.5 mg/d) | 1446/424 | Chronic hepatitis B (any stage) | 3.0/9.5 | Reduced HCC risk in cirrhotic patients |
| Kumada *et al*[[81](#_ENREF_81)] | Japan | Retrospective cohort | Lamivudine ± adefovir, entecavir | 117/117 | Chronic hepatitis B(any stage) | 12.3/11.6 | Reduced HCC risk |
| Sievert *et al*[[49](#_ENREF_49)] | Reg. trial (abstract) | Prospective cohort | Tenofovir(300 mg/d) | 641 | Chronic hepatitis B(any stage) | 6.0 | Reduced HCC risk compared to estimated risk (REACH-B model) |
| Su *et al*[[48](#_ENREF_48)] | Taiwan | Prospective cohort | Entecavir(0.5 mg/d) | 1123/503 | Cirrhosis(HBVDNA>2000 IU/ml) | 3.6/6.8 |  |
| Wu *et al*[[44](#_ENREF_44)] | Taiwan | Retrospective nationwide cohort | Lamivudine, adefovir or entecavir | 21595/21595 | Chronic hepatitis B(any stage) | 3.5/5.2 | Reduced HCC risk |
| Gordon *et al*[[82](#_ENREF_82)] | United States | Retrospective cohort | 94% received NAs, remaining received IFNs | 820/1851 | Chronic hepatitis B(any stage) | 5.2 | Reduced HCC risk |
| Coffin *et al*[[83](#_ENREF_83)] | United States | Retrospective cohort | NAs | 322 | Chronic hepatitis B(any stage) | 3.2 | Reduced HCC risk compared to estimated risk (REACH-B model) |

NAs: Nucleos(t)ide analogues; HCC: Hepatocellular carcinoma; T: Treatment group; C: Control group; pts: Patients; RCT: Randomized-controlled trial; HBeAg: Hepatitis B e antigen; SVS: Sustained virological suppression; IFNs: Interferons.

**Table 2** **Systematic review and meta-analyses investigating HCC risk reduction in patients receiving nucleos(t)ide analogues *vs* untreated controls**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Number of studies** | **Number of patients (T/C)** | **OR (95%CI)** | ***P*** |
| Papatheodoridis *et al*[[51](#_ENREF_51)] | 3 | 1313 (779/534) | 0.43 (0.25-0.74) | 0.002 |
| Zhang *et al*[[52](#_ENREF_52)] | 6 | 3644 (2035/1609) | 0.26 (0.15-0.47) | < 0.00001 |
| Singal *et al*[[53](#_ENREF_53)] | 6 | 6877 (3306/3571) | 0.48 (0.38-0.61) | < 0.00001 |
| Sung *et al*[[54](#_ENREF_54)] | 5 | 2289 (1267/1022) | 0.22 (0.10-0.50) | 0.0003 |

HCC: Hepatocellular carcinoma; T: Treatment group; C: Control group.

|  |
| --- |
| **Table 3 Summary of controlled studies investigating the efficacy of nucleos(t)ide analogues in prevention of HCC recurrence after curative treatments** |
| **Ref.** | **Country** | **Study type** | **Antiviral treatment** | **Number of patients (T/C)** | **HCC treatment** | **Follow-up (T/C),****Mean/median (year)** | **Treatment outcome** |
| Piao *et al*[[69](#_ENREF_69)] | Japan | Retrospective cohort | Lamivudine(100 mg/d) | 30/40 | Resection or ablation/TACE  | Not specified | No risk reduction for HCC recurrenceBetter overall survival |
| Shuqun *et al*[[70](#_ENREF_70)] | China | Retrospective cohort | Lamivudine (100 mg/d) + thymosin α1 | 17/16 | Resection | 1-3 | Reduced HCC recurrence (NS) |
| Kuzuya *et al*[[71](#_ENREF_71)] | Japan | Retrospective cohort | Lamivudine(100 mg/d) | 16/33 | Resection or RFA | 3.2/2.7 | No risk reduction |
| Kubo *et al*[[72](#_ENREF_72)] | Japan | Retrospective cohort | Lamivudine(100 mg/d) | 14/10 | Resection | 2.1 | Higher tumor-free survival |
| Yoshida *et al*[[84](#_ENREF_84)] | Japan | Retrospective cohort | Lamivudine(100 mg/d) | 33/71 | RFA | 2.8/3.9 | No risk reduction |
| Hung *et al*[[85](#_ENREF_85)] | China | Retrospective cohort | Lamivudine(100 mg/d) | 10/62 | Resection | 1.6 | Reduced HCC recurrence |
| Koda *et al*[[86](#_ENREF_86)] | Japan | Retrospective cohort | Lamivudine or entecavir | 30/20 | Resection or ablation/TAE | 2.4/3.0 | No risk reduction for HCC recurrenceBetter overall survival |
| Chuma *et al*[[87](#_ENREF_87)] | Japan | Retrospective cohort | Lamivudine(100mg/day) | 39/64 | Resection or RFA | 2.9/4.4 | Reduced HCC recurrence |
| Li *et al*[[74](#_ENREF_74)] | China | Prospective cohort | Lamivudine ± adefovir | 43/36 | Resection | 1.0 | No risk reduction |
| Chan *et al*[[73](#_ENREF_73)] | China | Retrospective cohort | Lamivudine or entecavir | 42/94 | Resection | Not specified | Reduced HCC recurrence |
| Urata *et al*[[88](#_ENREF_88)] | Japan | Retrospective cohort | Not specified | 46/242 | Resection | 3.1 | Tumor-free survival is better *vs* pts with high viral load |
| Yang *et al*[[89](#_ENREF_89)] | China | Prospective cohort | Lamivudine, adefovir or entecavir | 142/188 | Resection | 4.0 | Reduced HCC recurrence |
| Wu *et al*[[75](#_ENREF_75)] | Taiwan | Retrospective nationwide cohort | Nucleoside analogue(s) | 518/4051 | Resection | 2.6/2.2 | Reduced HCC recurrence |
| Huang *et al*[[90](#_ENREF_90)] | China | Prospective cohort | Lamivudine, adefovir or entecavir | 865/175 | Resection (HBVDNA > 2000 IU/mL) | 3.5 | Better disease-free survival (borderline significance)Better overall survival |
| Huang *et al*[[68](#_ENREF_68)] | China | Retrospective cohort | Lamivudine, adefovir or entecavir | 150/1459 | Resection (HBVDNA < 2000 IU/mL) | 2.9-3.3 | Better disease-free survival |
| Ke *et al*[[91](#_ENREF_91)] | China | Retrospective cohort | Lamivudine(100 mg/d) | 141/337 | Resection | 2.0/1.9 | No risk reduction for HCC recurrenceBetter overall survival |
| Su *et al*[[92](#_ENREF_92)] | Taiwan | Retrospective cohort | Lamivudine, entecavir or pegylated interferon | 62/271 | Resection | 3.8 | Reduced HCC recurrenceBetter overall survival |
| Yin *et al*[[76](#_ENREF_76)] | China | 2 cohorts(RCT and NRC) | Lamivudine1(100 mg/d) | RCT: 81/82NRC: 215/402 | Resection | RCT: 3.3NRC: 1.98 | Reduced HCC recurrence and better overall survival in both cohorts |
| Yeh *et al*[[93](#_ENREF_93)] | Taiwan | Retrospective cohort | Entecavir, lamivudine, telbivudine, or combination | 490/3369 | Resection, RFA, PEI | 3.3/3.3 | No benefits for HCC progression or overall survival |
| Zhang *et al*[[94](#_ENREF_94)] | China | Retrospective cohort | Entecavir(0.5 mg/d) | 40/47 | Resection | 2.6 | Reduced recurrence if HCC ≤ 3 cm |
| Hann *et al*[[95](#_ENREF_95)] | United States | Retrospective cohort | Nucleos(t)ide analogues | 16/9 | Resection, RFA, PEI, TACE | 5.0 | Reduced HCC recurrenceBetter overall survival |
| Nishikawa *et al*[[96](#_ENREF_96)] | Japan | Retrospective cohort | Lamivudine, adefovir or entecavir | 99/32 | Resection, RFA, PEI | 3.5/4.0 | No risk reduction for HCC recurrenceBetter overall survival |
| Huang *et al*[[77](#_ENREF_77)] | China | RCT | Adefovir (10 mg/d)Switch to entecavir (18 pts) | 100/100 | Resection | 5.0 | Reduced HCC recurrenceBetter overall survival |
| Chong *et al*[[97](#_ENREF_97)] | China | Retrospective-prospective cohort | Nucleoside analog(s) | 254/150 | Resection | 3.3/3.6 | No risk reduction for HCC recurrenceBetter overall survival |

1Adefovir±lamivudine or entecavir for drug resistance; 213 patients with high viral load, 11 patients with low viral load. HCC: Hepatocellular carcinoma; T: Treatment group; C: Control group; NS: Not significant; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection; RCT: Randomized-controlled trial; NRC: Non-randomized cohort; pts: Patients; IFNs: Interferons.

**Table 4** **Summary of meta-analyses which investigated preventive effect of nucleos(t)ide analogues on HCC recurrence in patients who underwent curative treatments**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Number of studies** | **Number of patients****(T/C)** | **OR****(95%CI)** | ***P*** |
| Miao *et al*[[98](#_ENREF_98)] 1 year recurrence 2 year recurrence | 22 | 119 (46/73)119 (46/73) | 0.59 (0.24-1.43)0.82 (0.34-1.74) | 0.240.60 |
| Wong *et al*[[65](#_ENREF_65)] | 9 | 555 (204/347) | 0.59 (0.35-0.97) | 0.04 |
| Sun *et al*[[78](#_ENREF_78)] | 13 | 6350 (1227/5123) | 0.66 (0.54-0.80) | < 0.0001 |
| Zhou *et al*[[79](#_ENREF_79)] | 8 | 6127 (NS) | 0.69 (0.59-0.80) | < 0.00001 |

HCC: Hepatocellular carcinoma; T: Treatment group; C: Control group.



**Figure 1 Chronic inflammation in the liver is characterized by sustained damage leading to hepatocyte death/regeneration and tissue repair cycle.** Activation of inflammatory signaling with increased cytokine and growth factor production leads to oxidative stress which contributes to cellular damage. Cumulative damage to cellular structures, proteins and chromosomes alters genomic and epigenomic functions which can eventually induce hepatocarcinogenesis.



**Figure 2 Hepatitis B virus (HBV) has unique virus-specific mechanisms to induce carcinogenesis in the liver.** The integration of HBV-DNA into the host genome alters DNA expression by gene and/or chromosomal deletions/translocations, and epigenetic changes (aberrant DNA methylation, miRNA changes). Viral protein HBx may cause interference with transcription and signaling pathways leading to altered p53 mediated apoptosis and angiogenesis by up-regulation of vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 (HIF-1) and angiopoietin-2 (ANG2). HBV preS/S proteins cause endoplasmic reticulum (ER) stress and mitochondrial dysfunction leading to oxidative stress.